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Hereditary nonpolyposis colorectal cancer is an autosomal dominant condition caused by highly penetrant gene mutations.
It is characterized by increased susceptibility for a specific group of cancer, mainly colorectal cancer. The syndrome
originates from the inheritance of mutations in DNA mismatch repair genes. The most commonly affected genes in hereditary
nonpolyposis colorectal cancer are hMLH1 and hMSH2. Their deficient expression renders the cell susceptible to the
accumulation of many molecular defects, a condition which can be evaluated by the instability in sections of base repeats
in the genoma known as microsatellite instability. The molecular detection of hereditary nonpolyposis colorectal cancer is
possible in most of the highly suspicious cases. Genetic tests for hereditary nonpolyposis colorectal cancer also allow
characterization of the individual that bears the mutation within a family. The high cost and restricted availability of these
tests hamper their use for every person presenting colorectal cancer. Due to this fact, some clinical criteria have been
developed by a hereditary nonpolyposis colorectal cancer international organization to select families with a high probability
of carrying the mutation. Once families at risk are identified, they are encouraged to join a screening program that aims at
early detection of hereditary nonpolyposis colorectal cancer-related cancers, increasing the possibility of its prevention and
early detection.
KEYWORDS: Hereditary nonpolyposis colorectal cancer. Follow-up. Screening. Mismatch repair gene. Microsatellite
instability.
Hereditary nonpolyposis colorectal cancer (HNPCC),
also known as the Lynch syndrome, is characterized by in-
creased susceptibility to colorectal neoplasms and second-
arily to stomach, endometrial, ovarian, hepatobiliary, and
renal cancers.1,2 Colorectal cancers (CRC) occur earlier
(about 45 years of age), compared to subjects with sporadic
CRC (starting at 60 years of age).3,4 It is a highly penetrant
dominant autosomal condition,3,4 and once the syndrome
is diagnosed, these subjects have a 70% to 80% chance of
developing CRC and a 39% chanceof evolving endome-
trial cancer up to 80 years of age.3-5
Hereditary nonpolyposis colorectal cancer is of consid-
erable epidemiological importance. It is estimated that this
condition occurs in about 5% to 10% of patients with
CRC.6,7 If all families with this mutation were included, the
number of affected subjects would be considerably higher.
Although the genetic and hereditary bases are relatively
well defined, the clinical manifestations of HNPCC are not
specific to this disease, and diagnosis based solely on fam-
ily history of cancer is possible only in a minority of cases.
Nevertheless, CRC in patients with HNPCC presents
some traits that can help to identify high-risk subjects. For
example, tumor location tends to be proximal4,8 and
presents an abnormally high frequency of mucinous or sig-
net cells. Moreover, the adenoma-carcinoma sequence ap-
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pears to be accelerated,9,10,11 and there is a strong tendency
for development of synchronic and metachronic lesions.4,5
The genetic hallmark of HNPCC is the occurrence of mu-
tations in a set of genes responsible for a specific type of
DNA repair, called the mismatch repair (MMR) system. It is
not rare to observe some errors during base pair arrangements
that take place during the process of DNA replication. This
phenomenon does not usually result in cell damage because
of the MMR system, which comprises a unit of at least 6 pro-
teins, encoded by the following genes: MLH1, MSH2, MSH3,
MSH6, PMS1, and PMS2. The proteins of the MMR system
act in a coordinated manner to identify minor reading errors
on the replicated DNA strand, proceeding to the elimination
of damaged DNA and substitution of a sequence that is per-
fectly paired with the mother strand.9,12,14 Most of HNPCC
cases are due to mutations that inactivate the MSH2 and
MLH1 genes, the former being responsible for 50%, the lat-
ter for 30% of the cases. 12,13 Cases of HNPCC involving other
genes of the MMR complex have been described, but are
much less common. Great interest has been aroused by stud-
ies which observed that mutations of the MSH6 gene in-
crease susceptibility to endometrial carcinoma in families
with a history of HNPCC.9,12
Microsatellites, defined as short repeated base sequences
present in non-codifying regions of DNA and whose func-
tion is as yet unknown, are one of the DNA regions most
affected by replication error. In the presence of mutated
MMR genes, the microsatellite copies of the daughter cells
may not be identical to the mother cells. This variation in
the extension of these repetitive sequences compared to the
normal DNA12,14,15 results in the so-called microsatellite in-
stability, or replication error. Studies show that about 90%
of cancers due to a mutation in hMLH1 and hMSH2 dis-
play microsatellite instability.14
CLINICAL DIAGNOSIS
Currently, diagnosis of HNPCC is made based predomi-
nantly on a detailed family history of cancer according to
criteria established by the International Collaborative Group
on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC)
known as the Amsterdam Criteria I and II13,16 (Table 1). They
are highly specific criteria that are simple to apply.
Nonetheless, because they are very restrictive,3,5,17 a
large number of affected families are excluded (i.e., small
families or those whose history is difficult to obtain). Ad-
ditionally, the Amsterdam Criteria help to define affected
families, but they do not allow identification of affected
individuals within an HNPCC family.
Recently, genetic tests that can identify HNPCC carri-
ers have become available, which permit the diagnosis of
the syndrome regardless of a family history. However, this
type of test can not be applied in all cases of CRC because
of its high cost and paucity of qualified laboratories capa-
ble of performing it. In order to aim these sophisticated tests
towards a selected group of subjects with higher probabil-
ity of HNPCC, new criteria were developed, termed the
Bethesda guidelines.17,18 The objective of these guidelines
was not the clinical diagnosis of the syndrome, but the iden-
tification of those patients who should undergo more de-
tailed laboratory investigation (Table 2).
LABORATORY DIAGNOSIS
The establishment of a genetic diagnosis of HNPCC has
filled the gaps left by the syndrome’s investigative clinical
Table 2 - Bethesda criteria17.
1. Individuals with cancer that belong to families that fulfill the
Amsterdam Criteria;
2. Individuals with two or more cancers related to HNPCC, including
synchronic and metachronic CRC and related* extracolonic cancers;
3. Individuals with CRC and a first-degree family member with CRC
and/or extracolic cancer related to HNPCC and/or colorectal
adenoma; one of the cancers diagnosed before age 45 and the
adenoma before age 40;
4. Individuals with CRC or endometrial carcinoma diagnosed before
age 45**;
5. Individuals with right colon CRC with undifferentiated
histopathology (solid/cribriform) diagnosed before age 45**;
6. Individuals with CRC with signet cell features diagnosed before
age 45+++;
7. Individuals with adenomas diagnosed before age 40.
*Endometrium, ovarian, stomach, hepatobiliary, small bowel,
transitional cell carcinoma of the pelvis or ureter.
**Solid/cribriform defined as little or undifferentiated carcinoma
composed of irregular leaflets and solid areas of large eosinophilic
cells containing small spaces similar to glands.
***Composed of over 50% of signet cells.
Table 1 - Amsterdam criteria I and II16.
Amsterdam I
• At least three family members must have histologically
confirmed colorectal cancer:
• One must be a first-degree relative of the other two;
• At least two consecutive generations must be affected;
• At least one of the CRC cases must have been diagnosed before
age 50;
• Familial adenomatous polyposis must be excluded.
Amsterdam II
• At least three family members must have a cancer associated
with HNPCC (colorectal, endometrial, urothelial, or small
bowel);
• One must be a first degree relative of the other two;
• At least two successive generations must be affected;
• At least one of the relatives with cancers associated with
HNPCC must have been diagnosed before age 50;
• Familial adenomatous polyposis should be excluded.
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criteria. Currently, the genetic tests enable us to not only
accurately diagnose the major group of families with un-
confirmed history, but also to investigate the presence or
absence of mutations in each family.
The main tests now available for investigating the syn-
drome are:
• Microsatellite instability test (MSI)14,19 screening for
HNPCC— Accomplished in paraffin-block tumor speci-
mens, they require microdissection of tumor tissue and
adjacent normal tissue by an experienced pathologist,
followed by extraction of DNA from both samples and
performance of polymerase chain reaction (PCR) in dif-
ferent microsatellite regions. The test comprehends a
panel of markers proposed by the International Collabo-
rative Group on HNPCC (the microsatellite regions sug-
gested by the panel are: BAT25, BAT26, DS123,
D5S346, and D17S250), that permit classification of ris-
ing instability (MSI-H), when 30% or more markers are
unstable, low (MSI-L) when instability is up to 30%, or
absent (MSS), when there is no instability. Tumors as-
sociated with HNPCC almost always demonstrate a high
degree of instability.20
• Immunohistochemistry for proteins of DNA repair genes
(lH)—Normal tissues express large amounts of MLH1
and MSH2 proteins in the nucleus. Interruption of the
protein by mutations results in reduction in their nu-
clear levels, and 50% of cases of HNPCC display this
reduction or absence of lH in paraffin specimens.14,21
Therefore, similar to MSl, this test is also performed as
a screening test from tumor specimens; that is, it can
only be performed in probands, and not in their healthy
relatives.
• DNA sequencing14,22—This is the gold standard for de-
tection of mutations. It consists of comparing each pair
of bases of a gene, or part of it, in blood samples to the
corresponding region of normal DNA. Despite its great
accuracy, it has a sensitivity of 70%,20,22 even when per-
formed in highly selected subjects with clinical diag-
nosis of HNPCC based on the Amsterdam criteria. Ad-
ditionally, DNA sequencing remains an expensive and
time consuming technique. Even so, once a mutation is
detected in a proband, the other relatives can be tested
at a lower cost and within a shorter time period, since
the study can then be performed in only the mutated
region.
Despite the genetic development observed in HNPCC
diagnosis, there are cases in which the diagnosis remains
difficult, due to the large variety of family histories and con-
troversial questions that may face the physician. In addi-
tion, the laboratory methods still present considerably high
rates of false-positive and false-negative results.
An algorithm for the management of an affected indi-
vidual is proposed in Figure 1. Initially immunohistochemi-
cal tests are routinely performed because of their simplic-
Figure 1 - Algorithm for Hereditary nonpolyposis colorectal cancer (HNPCC) diagnosis20.
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ity and lower cost. If the result is negative or if these tests
are not available, the MSI is performed. DNA sequencing
is reserved for cases with a positive immunohistochemical
or MSI test (Table 3).
SCREENING OF AFFECTED FAMILIES
Families that fulfill the Amsterdam criteria or at least 1
of the Bethesda guidelines criteria with MSI-H, besides
those known to be carriers of mutations in 1 of the repair
genes related to HNPCC, should undergo screening pro-
grams. When the MSI test is not available, it is also advis-
able to screen families that fulfill at least 2 of the Bethesda
criteria, especially those related to probands diagnosed with
cancer at an early age. In families undergoing genetic in-
vestigation, only members known to be carriers of muta-
tions need to be screened.20
Even in those familes that usually do not display
extracolic tumors, all the organs commonly affected by
HNPCC should be analyzed periodically. The beginning of
the examinations is usually defined as 10 years before the
age of tumor diagnosis in the family.
The ICG-HNPCC (International Collaborative Group on
HNPCC) recommends colonoscopies annually or every 2
years starting at age 25 (or every 5 years before the age of
appearance of CRC in the youngest affected individual in
the family) for first-degree relatives of HNPCC carriers. Ad-
ditionally, annual screening for endometrial cancer is rec-
ommended for women (transvaginal ultrasonography or en-
dometrial aspiration) starting at 30 years of age (Table 3).
CONCLUSION
Identifying individuals and families at high risk of de-
veloping diseases associated with high morbidity and mor-
tality is a very important goal in public health. In situa-
tions where the early detection of the disease is possible,
as in the case of hereditary cancer syndromes such as
HNPCC, the mortality and incapacitation levels can be
significally reduced with the implementation of the right
screening strategies. In addition, this policy results in lower
costs when compared to costs of the treatment of advanced
colorectal cancer.
The judicious evaluation of the family history of pa-
tients with colorectal cancer allows the correct use of more
specific and sophisticated tests that can improve manage-
ment of families with histories of HNPCC. Therefore, the
efforts of health professionals in investigating and motivat-
ing families to join screening programs are extremely im-
portant.
Table 3 - Guidelines recommended by ICG-Hereditary
nonpolyposis colorectal cancer for preventive examinations
and early diagnosis of colorectal cancer and extracolic
tumors25.
Organ Examination Start (Age) Frequency
Colon & Rectum colonoscopy - 20-25 Each 2 years
Endometrium gynecological 30-35 1-2 years
examination,
endovaginal
ultrasonography
Ovaries Ultrasonography 30-35 1-2 years
of pelvis, CA 125
Urinary tract ultrasonography, 30-35 2-3 years
urine I
Stomach gastroendoscopy 30-35 1-2 years
RESUMO
Silva RV e, Garicochea B, Cotti G, Maranho IC, Cutait R.
Câncer colo-retal hereditário não polipose - Diagnóstico e
surgimento de famílias de alto risco. Clinics.
2005;60(3):251-6.
O câncer colo-retal hereditário não polipose é uma síndrome
genética caracterizada por uma susceptilidade aumentada
para certos tipos específicos de câncer, especialmente o
câncer colo-retal. Ao nível molecular, a síndrome caracteriza-
se pela herança autossômica dominante de mutações em
genes envolvidos em um mecanismo de reparo do DNA
dirigido para defeitos em trocas, ganhos ou perdas de um
número de pequeno de bases, chamado de sistema de reparo
de erros de pareamento. Os genes mais comumente afetados
em câncer colo-retal hereditário não polipose são hMLH1 e
hMSH2, e sua inativação destina a célula portadora à
acumulação de mutações, uma condição conhecida como
fenótipo de erro de replicação. Estas mutações múltiplas
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serão transmitidas e amplificadas em células-filhas e sua
identificação pode ser feita por meio da identificação de
distúrbios em seqüências repetidas de DNA chamadas de
microssatélites. Células portadoras de defeitos deste tipo em
seus microssatélites apresentam um fenótipo denominado de
instabilidade de microssatélites (também denominado
fenótipo MSI). Por meio da detecção destes defeitos
genéticos é possível, presentemente, a realização de um
diagnóstico preciso de câncer colo-retal hereditário não
polipose, permitindo a atuação preventiva em portadores da
síndrome que ainda não desenvolveram câncer. Contudo,
limitações financeiras e de acesso aos exames inviabilizam
sua realização em todos os indivíduos que apresentam câncer
colo-retal. Por isso, foram estabelecidos pela comunidade
internacional alguns critérios que selecionam as famílias com
alta probabilidade de possuírem a mutação e que, portanto,
podem beneficiar-se com estes exames. Este artigo procura
abordar as estratégias recomendadas para identificação de
casos de alto risco de câncer colo-retal hereditário não
polipose, os testes genéticos disponíveis para estes casos e
as recomendações para prevenção e seguimento destas
famílias.
UNITERMOS: Câncer colo-retal hereditário não polipose.
Seguimento. Rastreamento. Sistema de reparo de erros
de pareamento. Instabilidade de microssatélites.
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